Debio Recherche Pharmaceutique S.A., commonly known as Debiopharm, is a prominent biopharmaceutical company headquartered in Switzerland (CH). Founded in 1971, Debiopharm has established itself as a leader in the development of innovative therapies for oncology and infectious diseases, focusing on both drug development and the commercialisation of novel treatments. With a strong presence in Europe and North America, Debiopharm is renowned for its commitment to advancing healthcare through cutting-edge research and development. The company’s core products include targeted therapies and companion diagnostics, which are distinguished by their precision and efficacy. Debiopharm's notable achievements include successful partnerships and collaborations that have propelled its market position, making it a key player in the biopharmaceutical industry. Through its dedication to improving patient outcomes, Debiopharm continues to shape the future of medicine.
How does Debio Recherche Pharmaceutique S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Debio Recherche Pharmaceutique S.A.'s score of 26 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Debio Recherche Pharmaceutique S.A., headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Debio Recherche Pharmaceutique S.A. may inherit climate commitments and emissions data from its parent organisation; however, no specific details or figures have been provided regarding these cascaded data sources. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and climate action, often setting science-based targets to reduce their carbon footprints. While Debio Recherche Pharmaceutique S.A. has not disclosed any such initiatives or commitments, the industry trend suggests a growing emphasis on environmental responsibility.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Debio Recherche Pharmaceutique S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
